Drugs / Aspirin
Aspirin
DrugAspirin (acetylsalicylic acid) is a nonsteroidal anti-inflammatory drug used for pain, fever, inflammation, and antithrombotic prevention. It is widely available as an over-the-counter medicine in many jurisdictions and remains one of the most used medicines globally. It also has long-term preventive use in selected cardiovascular patients.
- Trials
- 1130
- Recruiting
- 112
- Completed
- 582
- With results
- 208
Last revised
Pipeline
Phase by status
| Phase | Recruiting | Not yet | By invitation | Active | Completed | Terminated | Withdrawn | Suspended | Unknown | No longer available | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Early Phase 1 | 4 | 1 | 1 | 6 | 21 | 4 | — | 1 | 5 | — | 43 |
| Phase 1 | 3 | — | — | 1 | 70 | 3 | 2 | 1 | 4 | — | 84 |
| Phase 1/2 | — | 2 | — | 2 | 8 | 1 | — | — | 3 | — | 16 |
| Phase 2 | 11 | 2 | — | 7 | 89 | 18 | 6 | 1 | 16 | — | 150 |
| Phase 2/3 | 2 | 3 | — | 1 | 16 | 1 | — | — | 20 | — | 43 |
| Phase 3 | 34 | 14 | — | 6 | 104 | 25 | 9 | — | 33 | — | 225 |
| Phase 4 | 40 | 17 | 2 | 6 | 166 | 22 | 7 | — | 75 | — | 335 |
| Not applicable | 11 | 5 | — | 7 | 75 | 12 | 8 | — | 44 | — | 162 |
| Unknown | 7 | 1 | — | 1 | 33 | 2 | 3 | — | 24 | 1 | 72 |
Trials started per year
Conditions studied, by phase
| Condition | Early Phase 1 | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | Phase 4 | Not applicable | Unknown | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Coronary Artery Disease | 1 | 4 | — | 5 | 1 | 15 | 64 | 14 | 14 | 118 |
| Stroke | — | 3 | — | 3 | 7 | 30 | 23 | 9 | 6 | 81 |
| Ischemic Stroke | — | 5 | — | 5 | 10 | 23 | 20 | 4 | 11 | 78 |
| Cardiovascular Diseases | 1 | 4 | 1 | 7 | — | 12 | 24 | 9 | 4 | 62 |
| Pre-Eclampsia | 3 | — | 2 | 5 | 1 | 13 | 17 | 11 | 2 | 54 |
| Acute Coronary Syndrome | — | 4 | — | 3 | — | 6 | 26 | 3 | 3 | 45 |
| Myocardial Infarction | — | — | 1 | 6 | 1 | 12 | 18 | 1 | 4 | 43 |
| Thrombosis | 1 | 3 | — | 5 | — | 7 | 16 | 6 | 5 | 43 |
| Peripheral Arterial Disease | 1 | — | — | 2 | — | 6 | 13 | 7 | 6 | 35 |
| Atrial Fibrillation | — | — | — | 2 | — | 10 | 16 | 3 | 2 | 33 |
Most active sponsors
| # | Sponsor | Trials | Phase 3 |
|---|---|---|---|
| 1 | Bayer | 37 | 13 |
| 2 | AstraZeneca | 13 | 2 |
| 3 | Assiut University | 12 | 2 |
| 4 | Xijing Hospital | 12 | 4 |
| 5 | Beijing Tiantan Hospital | 11 | 8 |
| 6 | Bristol-Myers Squibb | 11 | 1 |
| 7 | Assistance Publique - Hôpitaux de Paris | 10 | 6 |
| 8 | Boehringer Ingelheim | 10 | 4 |
| 9 | National Cancer Institute (NCI) | 10 | 0 |
| 10 | Peking Union Medical College Hospital | 9 | 1 |
Most studied interventions
| # | Intervention | Trials |
|---|---|---|
| 1 | Aspirin | 1130 |
| 2 | Clopidogrel | 289 |
| 3 | Ticagrelor | 101 |
| 4 | Rivaroxaban | 69 |
| 5 | Warfarin | 37 |
| 6 | Cilostazol | 35 |
| 7 | Atorvastatin | 32 |
| 8 | Prasugrel Hydrochloride | 26 |
| 9 | apixaban | 25 |
| 10 | Enoxaparin | 22 |
Evidence
- Results reported
- 35.7%208 of 582 completed
- Published
- 17.9%104 of 582 completed
- Primary endpoint met
- 43.9%58 of 132 analyses
- Median months to report
- 16
Documents disclosed
Trial profile
- Median enrollment
- 126
- Median duration
- 34.3months
- Countries
- 96
- Study sites
- 11893
Who is enrolled
Median enrollment by phase
- Early Phase 1
- 47
- Phase 1
- 40
- Phase 1/2
- 49
- Phase 2
- 62
- Phase 2/3
- 100
- Phase 3
- 468
- Phase 4
- 194
- Not applicable
- 100
- Unknown
- 402
Where trials run
Busiest cities
| # | City | Country | Trials |
|---|---|---|---|
| 1 | New York | United States | 68 |
| 2 | Beijing | China | 65 |
| 3 | Seoul | South Korea | 60 |
| 4 | Boston | United States | 55 |
| 5 | Houston | United States | 51 |
| 6 | Philadelphia | United States | 48 |
| 7 | Baltimore | United States | 42 |
| 8 | Chicago | United States | 41 |
| 9 | Paris | France | 41 |
| 10 | Shanghai | China | 41 |
Terminations
- Terminated
- 88
- Withdrawn
- 35
- Suspended
- 3
- Stopped for recruitment
- 3.1%35 of 1130 trials
Stated reasons
Reasons are grouped from the sponsor's own wording with a rule-based classifier; the original text is shown below.
Recently stopped
| Trial | Status | Stated reason | Stopped |
|---|---|---|---|
| NCT03186456 Suspended | Suspended | Others | 2027-12-31 |
| NCT06290765 Withdrawn | Withdrawn | In alignment with company strategic direction. | 2027-06-30 |
| NCT05080946 Suspended | Suspended | Study drug is expiring. Will reopen when new drug is received. | 2026-12-31 |
| NCT04308551 Withdrawn | Withdrawn | shortage of funds | 2026-12-30 |
| NCT03729401 Terminated | Terminated | Testing supplies unavailable. | 2026-02-26 |
| NCT05104229 Withdrawn | Withdrawn | Limited Resources | 2026-01-01 |
| NCT03796156 Terminated | Terminated | Planned recruitment total was not achievable within the funded timeframe | 2025-09-23 |
| NCT04188119 Withdrawn | Withdrawn | Unable to open | 2025-05-31 |
| NCT06280976 Withdrawn | Withdrawn | study withdrawn, no participants enrolled, changes in the study design planned | 2025-01-01 |
| NCT04217447 Terminated | Terminated | The sponsor's decision to stop the study follows the DSMB's recommendations (end of enrolment and experimental treatment, post-treatment/end-of-study visit within 3 months of stopping treatment), regarding the benefit-risk balance. | 2024-10-28 |
Trial records
Individual study records live on ClinicalTrials.gov. A sample of the trials counted above: